Park Hyun Ho
College of Pharmacy, Chung-Ang University, Seoul, 06974, Republic of Korea.
Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, 06974, Republic of Korea.
Arch Pharm Res. 2021 May;44(5):475-486. doi: 10.1007/s12272-021-01330-w. Epub 2021 May 10.
Several studies have been conducted over the years to unravel the structural information on the receptors that bind to tumor necrosis factor receptor-associated factor (TRAF) and the driving forces for the TRAF/receptor complex. In addition, studies have also been performed to highlight the influence of TRAF malfunctioning and mutations on the development of human disease. However, a holistic study that systematically summarizes the available information and the existing clinical trends towards development of the TRAF-targeting drugs has not been conducted to date. Herein, I reviewed existing research that focused on the structural information of various receptors recognized by the different members of the TRAF family. I also reviewed studies on the different human diseases that occur due to TRAF malfunctioning or mutations as well as the clinical trials undertaken to treat TRAF-associated diseases.
多年来已经进行了多项研究，以揭示与肿瘤坏死因子受体相关因子（TRAF）结合的受体的结构信息以及TRAF/受体复合物的驱动力。此外，也开展了一些研究来突出TRAF功能失调和突变对人类疾病发展的影响。然而，迄今为止尚未进行一项全面的研究，系统地总结关于TRAF靶向药物开发的现有信息和当前临床趋势。在此，我回顾了专注于TRAF家族不同成员所识别的各种受体结构信息的现有研究。我还回顾了关于因TRAF功能失调或突变而发生的不同人类疾病的研究，以及为治疗TRAF相关疾病而进行的临床试验。
